The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer’s disease: a literature review
Open accessThe DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
The extracellular buildup of amyloid beta (Aβ) plaques in the brain is a hallmark of Alzheimer’s disease (AD). Detection of Aβ pathology is essential for AD diagnosis and for identifying and recruiting research participants for clinical trials evaluating disease-modifying therapies. Currently, AD diagnoses are usually made by clinical assessments, although detection of AD pathology with positron emission tomography (PET) scans or cerebrospinal fluid (CSF) analysis can be used by specialty clinics. These measures of Aβ aggregation, e.g. plaques, protofibrils, and oligomers, are medically invasive and often only available at specialized medical centers or not covered by medical insurance, and PET scans are costly. Therefore, a major goal in recent years has been to identify blood-based biomarkers that can accurately detect AD pathology with cost-effective, minimally invasive procedures. To assess the performance of plasma Aβ assays in predicting amyloid burden in the central nervous system (CNS), this review compares twenty-one different manuscripts that used measurements of 42 and 40 amino acid-long Aβ (Aβ42 and Aβ40) in plasma to predict CNS amyloid status. Methodologies that quantitate Aβ42 and 40 peptides in blood via immunoassay or immunoprecipitation-mass spectrometry (IP-MS) were considered, and their ability to distinguish participants with amyloidosis compared to amyloid PET and CSF Aβ measures as reference standards was evaluated. Recent studies indicate that some IP-MS assays perform well in accurately and precisely measuring Aβ and detecting brain amyloid aggregates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Timeline of Aβ studies [7, 10–25]. Timeline denoting significant events surrounding plasma Aβ use as a biomarker in AD diagnosis, color-coded by assay type. Results were conflicting for many years, but recent IP-MS studies provide promising AUC values for plasma Aβ42/40 measures. The diagnostic reference standard used in each study is listed in parentheses. For studies that used PET as a reference, the tracers include Pittsburg Compound B [7, 17–21, 25], flutemetamol [17, 20, 22, 23], florbetapir [17, 18, 20, 22, 24], and florbetaben [20]. Abbreviations: Disc., Discovery; Val., Validation. Figure created with BioRender.com](https://figures.cochat.ai/paper-figures/1a965f133bc8475cab0745183c127e55/the-performance-of-plasma-amyloid-beta-measurements-in-identifying-amyloid-figure-1.jpg)

![Fig. 3 Forest plots of all AUC values with PET and CSF references. The points are categorized and color-coded by assay type, and the horizontal bars represent a 95% confidence interval. Blue is IP-MS assay, yellow is ECL, orange is an antibody-free LC-MS assay, green is ELISA, and red is SIMOA. The black diamond symbols represent the weighted average of the assays for each category, and within categories, the assay name is listed on the y-axis. The size of each point corresponds to the sample size of the cohort and the diagnostic accuracy of AUC values is depicted on a scale below the x-axis [27]. Abbreviations: WashU, Washington University; Univ. Got., University of Gothenburg](https://figures.cochat.ai/paper-figures/a6e2c3a3bb9f4c3abf3f8806db63b8b7/the-performance-of-plasma-amyloid-beta-measurements-in-identifying-amyloid-figure-3.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In the last several years, blood-based markers (BBMs) capable of detecting AD pathology have been developed16–18.”
From Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests (2024) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Receiver Operating Characteristic Curve in Diagnostic Test Assessment
Mandrekar, J. N. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181ec173d · Cited by 4,506
Measures of Diagnostic Accuracy: Basic Definitions.
Šimundić, A.-M. (2009) · PubMed Central · Cited by 1,810
High performance plasma amyloid-β biomarkers for Alzheimer's disease
Nakamura, A., Kaneko, N., Villemagne, V. L., Kato, T., Doecke, J., Doré, V., Fowler, C., Li, Q.-X., Martins, R., Rowe, C., et al. (2018) · Nature · doi:10.1038/nature25456 · Cited by 1,681
Self-citationPalmqvist, S., Janelidze, S., Quiroz, Y. T., Zetterberg, H., Lopera, F., Stomrud, E., Su, Y., Chen, Y., Serrano, G. E., Leuzy, A., et al. (2020) · JAMA · doi:10.1001/jama.2020.12134 · Cited by 1,603
Self-citationBiomarkers for neurodegenerative diseases
Hansson, O. (2021) · Nature Medicine · doi:10.1038/s41591-021-01382-x · Cited by 1,159
Self-citationBlood-based biomarkers for Alzheimer's disease: towards clinical implementation
Teunissen, C. E., Verberk, I. M. W., Thijssen, E. H., Vermunt, L., Hansson, O., Zetterberg, H., van der Flier, W. M., Mielke, M. M., & del Campo, M. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00361-6 · Cited by 1,045
Self-citationHigh-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis
Schindler, S. E., Bollinger, J. G., Ovod, V., Mawuenyega, K. G., Li, Y., Gordon, B. A., Holtzman, D. M., Morris, J. C., Benzinger, T. L. S., Xiong, C., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000008081 · Cited by 885 · cited 2×
“For studies that used PET as a reference, the tracers include Pittsburg Compound B [7, 17–21, 25], flutemetamol [17, 20, 22, 23], florbetapir [17, 18, 20, 22, 24], and florbetaben [20].”
MethodResultSelf-citationthe Dominantly Inherited Alzheimer Network, Barthélemy, N. R., Li, Y., Joseph-Mathurin, N., Gordon, B. A., Hassenstab, J., Benzinger, T. L. S., Buckles, V., Fagan, A. M., Perrin, R. J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0781-z · Cited by 651
Self-citationPlasma β-amyloid in Alzheimer's disease and vascular disease
Janelidze, S., Stomrud, E., Palmqvist, S., Zetterberg, H., van Westen, D., Jeromin, A., Song, L., Hanlon, D., Tan Hehir, C. A., Baker, D., et al. (2016) · Scientific Reports · doi:10.1038/srep26801 · Cited by 626
Self-citationHuman amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo
Bateman, R. J., Munsell, L. Y., Morris, J. C., Swarm, R., Yarasheski, K. E., & Holtzman, D. M. (2006) · Nature Medicine · doi:10.1038/nm1438 · Cited by 599
Self-citation
Research works printed but not linked: 2
- Clinical and Laboratory Standards Institute (CLSI). Quantitative measurement of proteins and peptides by mass dpectrometry. In: CLSI guideline C64 (ISBN 978-1-68440-110-9) [Print]. 1st ed. USA: Clinical and Laboratory Standards Institute; 2021.
- Kaneko N, Nakamura A, Yoda R, Kato T, Sekiya S, Ito K, et al. S. High concordance between plasma amyloid β biomarkers by IP-MALDI-MS and visual assessment of amyloid PET. San Diego: Poster presented at: Alzheimer’s Association International Conference; 2022.
Cited by
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
Jack, C. R., Andrews, J. S., Beach, T. G., Buracchio, T., Dunn, B., Graf, A., Hansson, O., Ho, C., Jagust, W., McDade, E., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13859 · Cited by 2,803
Self-citationBarthélemy, N. R., Salvadó, G., Schindler, S. E., He, Y., Janelidze, S., Collij, L. E., Saef, B., Henson, R. L., Chen, C. D., Gordon, B. A., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02869-z · Cited by 448
“Aβ PET was performed with the EMA/FDA-approved tracer [ 18 F]flutemetamol in the BioFINDER-2 cohort and with the FDA-approved tracer [ 18 F]florbetapir (AV45) or [ 11 C]Pittsburgh Compound B (PiB) in the Knight ADRC cohort.”
BackgroundMethodInfluentialSelf-citationSchindler, S. E., Galasko, D., Pereira, A. C., Rabinovici, G. D., Salloway, S., Suárez-Calvet, M., Khachaturian, A. S., Mielke, M. M., Udeh-Momoh, C., Weiss, J., et al. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-00977-5 · Cited by 290
Self-citationHampel, H., Hu, Y., Cummings, J., Mattke, S., Iwatsubo, T., Nakamura, A., Vellas, B., O’Bryant, S., Shaw, L. M., Cho, M., et al. (2023) · Neuron · doi:10.1016/j.neuron.2023.05.017 · Cited by 283
Self-citationHead‐to‐head comparison of leading blood tests for Alzheimer's disease pathology
(2024) · doi:10.1002/alz.14315 · Cited by 199
Metadata
- Authors
- Brand, A. L., Lawler, P. E., Bollinger, J. G., Li, Y., Schindler, S. E., Li, M., Lopez, S., Ovod, V., Nakamura, A., Shaw, L. M., Zetterberg, H., Hansson, O., & Bateman, R. J.
- Affiliations
- Washington University in St. Louis (US)
- National Center for Geriatrics and Gerontology (JP)
- University of Pennsylvania (US)
- Sahlgrenska University Hospital (SE)
- Lund University (SE)
- Corresponding author
- Bateman, Randall J.
- ORCID
- Venue
- Alzheimer's Research & Therapy
- Published
- 2022-12-27
- Volume
- 14
- Issue
- 1
- Pages
- 195-195
- ISSN
- 1758-9193 (ISSN-L)
- PMC
- PMC9793600
- OpenAlex
- W4312200695
- Cited by
- 151
- References
- 68
- Citations by year
- 2026: 28 · 2025: 47 · 2024: 53 · 2023: 23
- FWCI
- 4.23
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Alzheimer s Research & Therapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- European Commission (860197)
- Vetenskapsrådet (2016-00906)
- National Institute on Aging (R21AG067559, RF1AG061900, U19AG024904, R01AG070941, P30AG072979)
- National Institute of Mental Health (R01MH117114)
- National Institute of Neurological Disorders and Stroke (R01NS095773)
- H2020 European Research Council (681712)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Health Professions › Medical Laboratory Technology › Clinical Laboratory Practices and Quality Control
- Keywords
- Alzheimer's disease, amyloid-beta, plasma biomarkers, amyloid plaques, amyloid-beta 42, Aβ40, immunoprecipitation mass spectrometry, immunoassay, amyloid PET, cerebrospinal fluid amyloid, amyloidosis, blood-based diagnosis, diagnostic accuracy
- MeSH terms
- Alzheimer Disease, Amyloid, Brain, Humans, Peptide Fragments, Biomarkers, Amyloid beta-Peptides, Positron-Emission Tomography, Plaque, Amyloid, Amyloidogenic Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer’s disease: a literature review. https://app.cochat.ai/papers/10.1186/s13195-022-01117-1
- The paper
- Brand, A. L., Lawler, P. E., Bollinger, J. G., Li, Y., Schindler, S. E., Li, M., Lopez, S., Ovod, V., Nakamura, A., Shaw, L. M., Zetterberg, H., Hansson, O., & Bateman, R. J. (2022). The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer’s disease: a literature review. Alzheimer's Research & Therapy. https://doi.org/10.1186/s13195-022-01117-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.